Ipsen S.A. (OTCMKTS:IPSEY) Short Interest Up 107.1% in December

Ipsen S.A. (OTCMKTS:IPSEY) was the target of a large growth in short interest in December. As of December 31st, there was short interest totalling 2,900 shares, a growth of 107.1% from the December 15th total of 1,400 shares. Based on an average daily volume of 2,300 shares, the days-to-cover ratio is currently 1.3 days.

Ipsen Stock Performance

OTCMKTS IPSEY traded up $0.47 during trading on Thursday, reaching $31.68. The company’s stock had a trading volume of 612 shares, compared to its average volume of 790. Ipsen has a 12 month low of $27.00 and a 12 month high of $34.06. The firm has a 50 day moving average price of $29.03 and a 200 day moving average price of $29.67.

Ipsen Company Profile

Ipsen SA operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial.